MacroGenics doses first patient in Phase 1 trial of MGC030 ADC
Tweet Send to a Friend
MacroGenics, Inc. (NASDAQ: MGNX) announced that the first patient has been dosed in a Phase 1 study of MGC030, an ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




